Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

UPTAKE - Virtuel pleje: Virtuelt hjemmehospital med fjernovervågning for at reducere akut hospitalsindlæggelse (UPTAKE-VC)

5. november 2026 opdateret af: University of Calgary

Brug af personlig risiko og digitale værktøjer til at vejlede overgange efter akutte nyrehændelser - virtuel pleje: virtuelt hjemmehospital med fjernovervågning for at reducere akut hospitalsindlæggelse

Method: Randomized Controlled Trial Study Duration: 3 Years Study Centre(s) University of Calgary and University of Alberta Objectives: To fill care gaps by implementing strategies to reduce length of hospital stay, readmission rates, and improve long-term outcomes after Acute Kidney Injury (AKI). Number of Participants: Three Hundred and fifty four (n=354) Diagnosis and Main Inclusion Criteria: Hospitalized adults with AKI at high risk of hospital readmission or death

Study Intervention: Multi-component Digital Health Solutions, including:

  1. Computerized Clinical Decision Support (CDS) and
  2. Virtual Care Delivered through Hospital at Home (VC) Duration of administration: Determined by the Patient's clinical team Reference therapy: Usual Care Statistical Analyses: Descriptive Analysis, Regression

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

  1. Background and Rationale

    Acute kidney injury (AKI) is a common and serious complication in hospitals. A major care gap for survivors of AKI is the fragmentation of care that exists as they transition from the hospital to their home. This contributes to a high risk of adverse long-term outcomes, including prolonged hospitalization, high rates of readmission, cardiovascular events, infections, progression to chronic kidney disease (CKD), kidney failure requiring dialysis, and death.

    To address this challenge, the investigators are implementing multi-component digital health solutions including Computerized Clinical Decision Support (CDS) and Digital Remote Patient Monitoring (dRPM) through Virtual Care (VC) programs in Alberta to reduce length of hospital stay and readmission rates and improve long-term outcomes after AKI.

    Evidence of the effectiveness of the two digital health solutions is available from Alberta and international clinical trials. Our team previously implemented a computerized CDS intervention for AKI risk assessment and prevention and achieved improved AKI prevention and reduced AKI incidence after cardiac procedures across the province. The investigators will use a similar approach to identify high risk patients with AKI and provide recommendations to improve the quality of their care, which is well suited to the evolving digital health infrastructure in Alberta.

    Providing hospital-level care at home through Virtual Care (VC) teams has been shown to reduce mortality and readmission rates. Alberta's VC program have existed in both Edmonton and Calgary since 2018 and have reported lower readmission rates, Emergency Department (ED) visits and use of Emergency Medical Services than observed with usual care. Patients reported that the program helped them regain their independence and function. Alberta's VC programs have implemented dRPM technology, which has been further associated with fewer days in hospital and emergency department visits. Patients reported better quality of care using this technology. The framework for dRPM and complex care planning is already in place in Alberta's Virtual Care programs. The investigators intend to utilize these programs to improve transitions of care through early facilitated discharge and enhanced follow-up of patients with AKI at high risk of hospital readmission, who require frequent monitoring and more intensive care strategies during this vulnerable period of transition in care.

  2. Research Question and Objectives

    • Implement and evaluate a transition of care intervention for patients with AKI.
    • Integrate digital health solutions that can achieve levels of monitoring and care in a patient's own home that are comparable to acute care, while transitioning care to the community setting.
    • Reduce the length of hospital stay and risk of hospital readmission for people with AKI.
    • Improve the long-term outcomes after hospitalization with AKI.
  3. Methods

The investigators will evaluate implementation initially in a Vanguard phase to establish feasibility and acceptability of the intervention, followed by an evaluation of implementation and effectiveness of the intervention in a larger Multicenter Randomized Controlled Trial (RCT). High risk patients with AKI and a predicted risk of readmission or death ≥20% will be identified using a Best Practice Alert (BPA) in Connect Care and participants will be randomized to care with or without virtual monitoring through the VC programs. All patients will receive the same baseline interventions refined in the Vanguard phase, while the intervention arm will additionally receive VC with dRPM following discharge.

High risk patients in the intervention arm will be navigated through the transition of care pathway by a trained nurse navigator. Patients will receive dRPM kits, and biometric data will be automatically uploaded to the web-based monitoring platform and reviewed by the nurse navigator. Patients will receive regular virtual assessments via telephone or videoconferencing (via the tablet) after in-patient discharge. Blood tests will be drawn at home by community paramedics as deemed necessary by the clinical team to assess kidney function and monitor for complications of AKI. Should concerns be identified that warrant in-person assessment, paramedic care teams will be sent for assessment and/or intervention. Upon completion of the intervention patients will be assessed for readiness to move to the subacute arms of the program and return to their primary care provider. If ongoing nephrologist or other specialist care is required, the nurse navigator will ensure appropriate follow up is arranged.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

354

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Alberta
      • Calgary, Alberta, Canada, T2N 1N4
        • Rekruttering
        • University of Calgary
        • Kontakt:
        • Ledende efterforsker:
          • Matthew T James, MD PhD FRCPC
      • Edmonton, Alberta, Canada, T6G 2G3
        • Rekruttering
        • University of Alberta
        • Kontakt:
        • Ledende efterforsker:
          • Neesh Pannu, MD SM FRCPC

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Age ≥ 18 years old.
  • AKI identified in hospital using Kidney Disease Improving Global Outcomes (KDIGO) criteria17.
  • Hospitalization > 48 hours.
  • LACE (L= Length patient Stay in the hospital, A= Acuity of Admission of patient in the hospital, C= Comorbidity and E= Emergency Visit.) Score 12 or higher.
  • Meets all inclusion criteria of Virtual Home Hospital programs of Calgary and Edmonton zones.

Exclusion Criteria:

  • Non-Alberta residents.
  • Resides outside the catchment areas for the Calgary and Edmonton Virtual Home Hospital programs.
  • C1 or C2 goals of care.
  • Hospitalization > 30 days.
  • Will be discharged to long-term care.
  • Kidney failure receiving dialysis.
  • Already admitted in Virtual Home Hospital Program

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Sundhedstjenesteforskning
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Virtual Care

Participants will receive virtual care through Virtual Home Hospital programs in Alberta for their hospital to home transition of care.

Participants will go through Virtual hospital programs following the processes established by these programs in Alberta.

Ingen indgriben: Usual Care

Participants will be discharged as per usual care practices from hospital to their home.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
the number of days alive out of hospital
Tidsramme: Up to 45 days from the date of randomization

the number of days alive out of hospital

Up to 45 days from the date of randomization

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
the time as inpatient in hospital
Tidsramme: Up to 45 days from the date of randomization

the time as inpatient in hospital

Up to 45 days from the date of randomization
death
Tidsramme: from the date of randomization up to 45 days, or date of death from any cause, whichever came first,

death records from health administrative data.

from the date of randomization up to 45 days, or date of death from any cause, whichever came first,
hospital readmission
Tidsramme: Up to 45 days from the date of randomization

hospital readmission records from health administrative data.

Up to 45 days from the date of randomization
Emergency Department visits
Tidsramme: Up to 45 days from the date of randomization

Emergency Department visit records from health administrative data.

Up to 45 days from the date of randomization
Estimated Glomerular Filtration (eGFR)
Tidsramme: At 90 days after the date of randomization

eGFR

At 90 days after the date of randomization
Urine Albumin Creatinine Ration (ACR)
Tidsramme: At 90 days after the date of randomization

ACR laboratory test

At 90 days after the date of randomization
total number of physician visits
Tidsramme: Up to 45 days from the date of randomization

total number of physician visits

Up to 45 days from the date of randomization
number of physician visits by specialty
Tidsramme: Up to 45 days from the date of randomization

primary care vs. non-primary care

Up to 45 days from the date of randomization
Changes to medication prescription
Tidsramme: Up to 45 days from the date of randomization

Changes to medication prescription (including starting, stopping, or dose adjustment) of an Angiotensin-Converting Enzyme Inhibitors (ACEI)/Angiotensin receptor blockers (ARB), diuretic, SGLT2 inhibitor, or NSAID or administration of IV fluid

Up to 45 days from the date of randomization
laboratory testing
Tidsramme: Up to 45 days from the date of randomization

Number of creatinine/eGFR, electrolytes, and urine protein quantification

Up to 45 days from the date of randomization
patient experience care transition measure
Tidsramme: At 45 days after the date of randomization

Online Survey

At 45 days after the date of randomization
Euro Qol- 5 Dimension (EQ5D)
Tidsramme: At 45 days after the date of randomization

Online Survey to assess quality of life mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is scored on a 5-level severity ranking that ranges from "no problems" to "extreme problems

At 45 days after the date of randomization

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Matthew James, MD, University of Calgary

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

10. august 2024

Primær færdiggørelse (Anslået)

30. juni 2027

Studieafslutning (Anslået)

31. december 2027

Datoer for studieregistrering

Først indsendt

29. juli 2024

Først indsendt, der opfyldte QC-kriterier

2. august 2024

Først opslået (Faktiske)

5. august 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

10. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

5. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • REB23-0762

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .